Extravasation: A dreaded complication of chemotherapy

Annals of Oncology

Volumn 14, Issue SUPPL. 3, 2003, Pages

  Schrijvers, D L ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; RAZOXANE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AGED; ARTICLE; BLISTER; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER STAGING; CASE REPORT; CLINICAL EXAMINATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; EXTRAVASATION; FEMALE; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; OINTMENT; PAIN; PRIORITY JOURNAL; SKIN BURNING SENSATION; SOFT TISSUE SARCOMA; TISSUE REACTION;

EID: 0037622581     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg744     Document Type: Article

References (44)

1. Pattison J. Managing cytotoxic extravasation. Nurs Times 2002: 98: 32-34.
2. Lebredo L, Barrie R, Woltering EA. DMSO protects against adriamycin-induced tissue necrosis. J Surg Res 1992; 53: 62-65.
3. Hajaridadeh H, Lebredo L, Barrie R, Woltering EA. Protective effect of doxorubicin in vitamin C or dimethyl sulfoxide skin ulceration in pig. Ann Surg Oncol 1994; 1: 411-414.
4. Lawrence HJ, Walsh D, Zappotowski KA et al. Topical dimethyl sulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol 1989; 23: 316-318.
5. Olver IN, Aisner J, Hament A et al. A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. J Clin Oncol 1988; 6: 1732-1735.
6. Bertilli G, Gozza A, Forno GB et al. Topical dimethyl sulfoxide for the prevention of soft tissue injury after extravasation of vesicant drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851-2855.
7. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000; 6: 3680-3686.
8. Langer SW, Sehested M, Jansen PB et al. Dexrazoxane in anthracycline extravasation. J Clin Oncol 2000: 18: 3064.
9. Yilmaz M, Demirdover C, Mola F. Treatment options in extravasation injury: an experimental study in rats. Plast Reconstr Surg 2002; 109: 2418-2423.
10. Askar I, Erbas MK, Gurlek A. Effects of heparin fractions on the prevention of skin necrosis resulting from adriamycin extravasation; an experimental study. Ann Plast Surg 2002; 49: 297-301.
11. Disa JJ, Chang RR, Mucci SJ, Goldberg NH. Prevention of adriamycin-induced full thickness skin loss using hyaluronidase infiltration. Plast Reconstr Surg 1998; 101: 370-374.
12. Schwartsmann G, Sander EB, Vinholes J et al. N-Acetylcysteine protects skin lesion induced by local extravasation of doxorubicin in a rat model. Am J Pediatr Hematol Oncol 1992; 14: 280-281.
13. Lucero MJ, Vigo J, Rabasco AM et al. Protection by α-tocopherol against skin necrosis induced by doxorubicin hydrochloride. Pharmazie 1993; 48: 772-775.
14. Eroglu E, Sari A, Altuntas I et al. The effect of GM-CSF (granulocyte macrophage colony stimulating factor) on doxorubicin-induced tissue necrosis and wound healing. Indian J Cancer 2000; 37: 153-157.
15. Vargel I, Erdem A, Ertoy D et al. Effects of growth factors on doxorubicin-induced skin necrosis: documentation of histomorphological alteration and early treatment by GM-CSF and G-CSF. Ann Plast Surg 2002; 49: 646-653.
16. Ulutin HC, Guden M, Dede M, Pak Y. Comparison of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers. Eur J Gynaecol Oncol 2000; 21: 613-615.
17. Monstrey SJ, Mullick P, Naranyanan K, Ramasastry SS. Hyperbaric oxygen therapy and free radical production: a experimental study in doxorubicin (adriamycin) extravasation injuries. Ann Plast Surg 1997; 38: 163-168.
18. Aktas S, Toklu AS, Olgac V. Hyerbaric oxygen therapy in adriamycin extravasation: a experimental animal study. Ann Plast Surg 2000; 45: 167-171.
19. Heitmann C, Durmus C, Ingianni G. Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg 1998; 23: 666-668.
20. Hankin FM, Louis DS. Surgical management of doxorubicin (adriamycin) extravasation. J Pediatr Orthop 1984; 4: 96-99.
21. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985; 75: 397-405.
22. Andersonn AP, Dahlstrom KK. Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer 1993; 29A: 1712-1714.
23. Scuderi N, Onesti M. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 1994; 32: 39-44.
24. Tsavaris N, Komitsopoulou P, Karagiaouris P et al. Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. Cancer Chemother Pharmacol 1992; 30: 330-333.
25. Heckler F. Current thoughts on extravasation injuries. Clin Plast Surg 1989; 16: 557-563.
26. Dorr R. Antidotes to vesicant chemotherapy extravasations. Blood Rev 1990; 4: 41-60.
27. Bikkers TH, Verweij J, van Geel AN, Stoter G. Severe tissue necrosis due to extravasation of mitomycin. Ned Tijdschr Geneeskd 1987; 131: 588-590.
28. Patel JS, Krusa M. Distant and delayed mitomycin C extravasation. Pharmacotherapy 1999; 19: 1002-1005.
29. Aizawa H, Tagami H. Delayed tissue necrosis due to mitomycin C. Acta Derm Venereol 1987; 67: 364-366.
30. Murakami Y, Shibata S, Koso S et al. Delayed tissue necrosis associated with mitomycin-C administration. J Dermatol 2000; 27: 413-415.
31. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety 1995; 12: 245-255.
32. Alberts DS, Dorr RT. Case report: topical DMSO for mitomycin C-induced skin ulceration. Oncol Nurs Forum 1991; 18: 693-695.
33. Ludwig CU, Stoll HR, Obrist R, Obrecht JP. Prevention of cytotoxic drug-induced skin ulcers with dimethyl sulfoxide and α-tocopherole. Eur J Cancer Clin Oncol 1987; 23: 327-329.
34. Rentschler R, Wilbur D. Pyridoxine: a potential local antidote for Mitomycin-C extravasation. J Surg Oncol 1988; 37: 269-271.
35. Yama N, Tsuchida Y, Nuka S et al. Usefulness of magnetic resonance imaging for surgical management of extravasation of an antitumor agent: a case report. Jpn J Clin Oncol 2001; 31: 122-124.
36. Raley J, Geisler JP, Buekers TE, Sorosky JI. Docetaxel extravasation causing significant delayed tissue injury. Gynecol Oncol 2000; 78: 259-260.
37. Berghammer P, Pohnl R, Baur M, Dittrich C. Docetaxel extravasation. Support Care Cancer 2001; 9: 131-134.
38. Ascherman JA, Knowles SL, Attkiss K. Docetaxel (Taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 2000; 45; 438-441.
39. Dorr RT, Snead K, Liddil JD. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer 1996; 78: 152-156.
40. Barutca S, Kadikoylu G, Bolaman Z et al. Extravasation of paclitaxel into breast tissue from central catheter port. Support Care Cancer 2002; 10: 563-565.
41. Herrington JD, Figueroa JA. Severe necrosis due to paclitaxel extravasation. Pharmacotherapy 1997; 17: 163-165.
42. Raymond E, Cartier S, Canuel C et al. Extravasation of paclitaxel (Taxol). Rev Med Interne 1995; 16: 141-142.
43. Ajani JA, Dodd LG, Daughertyt K et al. Taxol-induced soft-tissue injury secondary to extravasation: characterisation by histopathology and clinical course. J Natl Cancer Inst 1994; 86: 51-53.
44. Dorr T. Antidotes to vesicant chemotherapy extravasation. Blood Rev 1990; 4: 41-60.